Celcuity, Inc. (NASDAQ:CELC) Sees Significant Growth in Short Interest

Celcuity, Inc. (NASDAQ:CELC) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 8,853,129 shares, an increase of 20.9% from the December 15th total of 7,321,648 shares. Currently, 22.7% of the company’s stock are short sold. Based on an average daily trading volume, of 840,129 shares, the short-interest ratio is currently 10.5 days. Based on an average daily trading volume, of 840,129 shares, the short-interest ratio is currently 10.5 days. Currently, 22.7% of the company’s stock are short sold.

Celcuity Stock Performance

CELC traded down $0.20 on Tuesday, reaching $106.76. 109,881 shares of the stock were exchanged, compared to its average volume of 590,917. The company has a debt-to-equity ratio of 2.74, a current ratio of 12.26 and a quick ratio of 12.26. The company’s 50-day moving average price is $100.48 and its 200 day moving average price is $66.37. The firm has a market capitalization of $4.94 billion, a PE ratio of -29.32 and a beta of 0.25. Celcuity has a fifty-two week low of $7.57 and a fifty-two week high of $116.44.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. As a group, sell-side analysts forecast that Celcuity will post -2.62 EPS for the current fiscal year.

Insider Transactions at Celcuity

In other news, Director Richard E. Buller sold 3,000 shares of the business’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $105.69, for a total value of $317,070.00. Following the completion of the transaction, the director directly owned 6,760 shares of the company’s stock, valued at approximately $714,464.40. The trade was a 30.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 15.78% of the company’s stock.

Institutional Investors Weigh In On Celcuity

Several hedge funds have recently added to or reduced their stakes in the business. Saturn V Capital Management LP increased its holdings in Celcuity by 8.4% in the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after acquiring an additional 91,843 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Celcuity by 2,142.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company’s stock worth $772,000 after buying an additional 14,930 shares in the last quarter. M Holdings Securities Inc. purchased a new position in shares of Celcuity in the second quarter valued at approximately $224,000. Corton Capital Inc. acquired a new stake in shares of Celcuity in the second quarter worth approximately $175,000. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of Celcuity during the third quarter worth approximately $399,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on CELC shares. Needham & Company LLC set a $95.00 target price on shares of Celcuity in a report on Monday, October 20th. Guggenheim started coverage on shares of Celcuity in a research note on Monday, September 22nd. They set a “buy” rating for the company. Wall Street Zen cut shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday, October 26th. Wolfe Research initiated coverage on shares of Celcuity in a report on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price target on the stock. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $105.25.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.